| Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M Krzakowski, E Laack, ... The Lancet 374 (9699), 1432-1440, 2009 | 1537 | 2009 |
| 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with … MS Aapro, J Bohlius, DA Cameron, L Dal Lago, JP Donnelly, N Kearney, ... European journal of cancer 47 (1), 8-32, 2011 | 1245 | 2011 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 947 | 2018 |
| Prediction of venous thromboembolism in cancer patients C Ay, D Dunkler, C Marosi, AL Chiriac, R Vormittag, R Simanek, ... Blood, The Journal of the American Society of Hematology 116 (24), 5377-5382, 2010 | 902 | 2010 |
| A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical … NI Cherny, R Sullivan, U Dafni, JM Kerst, A Sobrero, C Zielinski, ... Annals of Oncology 26 (8), 1547-1573, 2015 | 869 | 2015 |
| Trastuzumab beyond progression in human epidermal growth factor receptor 2–positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study G von Minckwitz, A du Bois, M Schmidt, N Maass, T Cufer, FE de Jongh, ... Journal of Clinical Oncology 27 (12), 1999-2006, 2009 | 850 | 2009 |
| Therapeutic vaccines for cancer: an overview of clinical trials I Melero, G Gaudernack, W Gerritsen, C Huber, G Parmiani, S Scholl, ... Nature reviews Clinical oncology 11 (9), 509-524, 2014 | 835 | 2014 |
| Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, ... Journal of Clinical Oncology 36 (1), 7, 2018 | 794 | 2018 |
| Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma M Schmidinger, CC Zielinski, UM Vogl, A Bojic, M Bojic, C Schukro, ... Journal of clinical oncology 26 (32), 5204-5212, 2008 | 688 | 2008 |
| EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and … MS Aapro, DA Cameron, R Pettengell, J Bohlius, J Crawford, M Ellis, ... European journal of cancer 42 (15), 2433-2453, 2006 | 652 | 2006 |
| Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment WJ Köstler, M Hejna, C Wenzel, CC Zielinski CA: a cancer journal for clinicians 51 (5), 290-315, 2001 | 621 | 2001 |
| Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma AS Berghoff, B Kiesel, G Widhalm, O Rajky, G Ricken, A Wöhrer, ... Neuro-oncology 17 (8), 1064-1075, 2015 | 586 | 2015 |
| ESMO-magnitude of clinical benefit scale version 1.1 NI Cherny, U Dafni, J Bogaerts, NJ Latino, G Pentheroudakis, ... Annals of oncology 28 (10), 2340-2366, 2017 | 563 | 2017 |
| Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer B Gruenberger, D Tamandl, J Schueller, W Scheithauer, C Zielinski, ... Journal of clinical oncology 26 (11), 1830-1835, 2008 | 537 | 2008 |
| D-dimer and prothrombin fragment 1+ 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study C Ay, R Vormittag, D Dunkler, R Simanek, AL Chiriac, J Drach, ... Journal of Clinical Oncology 27 (25), 4124-4129, 2009 | 536 | 2009 |
| Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer M Reck, A Luft, A Szczesna, L Havel, SW Kim, W Akerley, MC Pietanza, ... Journal of Clinical Oncology 34 (31), 3740-3748, 2016 | 514 | 2016 |
| High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) C Ay, R Simanek, R Vormittag, D Dunkler, G Alguel, S Koder, G Kornek, ... Blood, The Journal of the American Society of Hematology 112 (7), 2703-2708, 2008 | 510 | 2008 |
| Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial T Brodowicz, M Krzakowski, M Zwitter, V Tzekova, R Ramlau, N Ghilezan, ... Lung cancer 52 (2), 155-163, 2006 | 472 | 2006 |
| High D-dimer levels are associated with poor prognosis in cancer patients C Ay, D Dunkler, R Pirker, J Thaler, P Quehenberger, O Wagner, ... haematologica 97 (8), 1158, 2012 | 439 | 2012 |
| Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents F Andre, CC Zielinski Annals of oncology 23, vi46-vi51, 2012 | 388 | 2012 |
